Molecular models courtesy
Dr. Joseph W. Lauher,
SUNY Stony Brook
chemical structure of CPP-109
Vigabatrin model

About CPP-109

CPP-109 is Catalyst's designation for vigabatrin, a potential treatment for cocaine and other drug addictions. The FDA has accepted Catalyst's Investigational New Drug application to conduct clinical trials in the United States of CPP-109 for addictions (initially cocaine and methamphetamine) and has granted Fast Track status to CPP-109. To date, Catalyst has supported three completed human trials in Mexico. For information on those trials, see the links below.

Vigabatrin, also known as gamma vinyl-GABA or GVG, is marketed as Sabril® outside of North America by Sanofi-Aventis. Sabril is not approved for use in the U.S. Sabril is available in tablet and powder forms and used in combination therapy for specific types of epilepsy and alone in the management of infantile spasms (West Syndrome). Vigabatrin has been on the market during the last decade in more than 30 countries outside the United States.

CPP-109 works without the apparent side effects typically associated with GABA agonists. Targeting brain GABAergic systems with drugs such as CPP-109 is a potentially effective treatment for cocaine, methamphetamine and other substance dependencies.

 
Human brain scans showing the effect of cocaine use
on brain metabolism
courtesy Brookhaven National Laboratory
normal scanscan after 10 days of cocaine usescan after 100 days of cocaine use
Normal
brain metabolism		Brain metabolism
after 10 days
of cocaine use		Brain metabolism
after 100 days
of cocaine use
 

Read about our third Mexican trial:

Read about our second Mexican trial (PDF file).

Read about our first Mexican trial (PDF file).

Read a pilot study on CPP-109 and ocular safety (PDF file).

How CPP-109 works